427 A phase 1b/2 study of cabozantinib in combination with pembrolizumab in advanced melanoma

427 A phase 1b/2 study of cabozantinib in combination with pembrolizumab in advanced melanoma

Bibliographic Details
Main Authors:	Mohammed Milhem, Yousef Zakharia, Jayanshu Jain, Melanie Frees, Hesham Yasin, Jaime Bonner, Michele Freesmeier, Rohan Garje, Vyshak Alva Venur
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2020-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

Targeted Therapies for Brain Metastases from Breast Cancer
by: Vyshak Alva Venur, et al.
Published: (2016-09-01)

Multivariable Analysis of 169 Cases of Advanced Cutaneous Melanoma to Evaluate Antibiotic Exposure as Predictor of Survival to Anti-PD-1 Based Immunotherapies
by: Umang Swami, et al.
Published: (2020-10-01)

Pembrolizumab Therapy Triggering an Exacerbation of Preexisting Autoimmune Disease
by: Sneha D. Phadke DO, et al.
Published: (2016-10-01)

PARP Inhibitors in Prostate and Urothelial Cancers
by: Rohan Garje, et al.
Published: (2020-02-01)

Clinical Challenges with Talimogene Laherparepvec: Cured Lymph Nodes Masquerading as Active Melanoma
by: Umang Swami, et al.
Published: (2019-01-01)

PEMBROLIZUMAB IN THE TREATMENT OF METASTATIC MELANOMA
by: I. V. SAMOILENKO, et al.
Published: (2017-06-01)

Spotlight on pembrolizumab in the treatment of advanced melanoma
by: Rajakulendran T, et al.
Published: (2015-06-01)

Targeting Molecular Pathways in Intracranial Metastatic Disease
by: Vyshak Alva Venur, et al.
Published: (2019-03-01)

The Future of Immunotherapy-Based Combination Therapy in Metastatic Renal Cell Carcinoma
by: Rohan Garje, et al.
Published: (2020-01-01)

Pembrolizumab for the treatment of uveal melanoma: A case series
by: Yanina Jeanne Leona Jansen, et al.
Published: (2020-11-01)

Advanced melanoma in adults: Pembrolizumab as a treatment option
by: Antonio Silvinato, et al.

Vitiligo Repigmentation with Melanoma Progression During Pembrolizumab Treatment
by: Charlée Nardin, et al.
Published: (2019-07-01)

Challenging the standard of care in advanced melanoma: focus on pembrolizumab
by: Abdul-Karim RM, et al.
Published: (2017-09-01)

Remission of a Perimyocardial Melanoma Metastasis With Pembrolizumab Treatment
by: Frederik Uttenthal Larsen, MD, et al.
Published: (2019-06-01)

Cabozantinib: from studies to clinical practice
by: V. В. Matveev, et al.
Published: (2019-10-01)

Cabozantinib and apixaban: an hitherto unreported interaction
by: Daniele Santini, et al.
Published: (2019-09-01)

Durable Clinical Benefit in Patients with Advanced Cutaneous Melanoma after Discontinuation of Anti-PD-1 Therapies Due to Immune-Related Adverse Events
by: Umang Swami, et al.
Published: (2019-01-01)

Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma
by: Ramses Sadek, et al.
Published: (2021-06-01)

New developments in the management of advanced melanoma – role of pembrolizumab
by: Improta G, et al.
Published: (2015-09-01)

Lichen planopilaris associated with pembrolizumab in a patient with metastatic melanoma
by: Anna L. Cogen, MD, PhD, et al.
Published: (2018-03-01)

Identification of neutralising pembrolizumab anti-drug antibodies in patients with melanoma
by: S. C. Sasson, et al.
Published: (2021-09-01)

Efficacy of pembrolizumab for advanced/metastatic melanoma: a meta-analysis
by: Zhang Qi, et al.
Published: (2020-06-01)

Nutritional Status of 427 Malignant Tumor Patients
by: WEI Yujia, et al.
Published: (2018-01-01)

Regression of Intracranial Meningiomas Following Treatment with Cabozantinib
by: Rupesh Kotecha, et al.
Published: (2021-04-01)

243 Real world exposure survival relationship of pembrolizumab in metastatic melanoma
by: Vishal Navani, et al.
Published: (2020-11-01)

Predicting response to pembrolizumab in metastatic melanoma by a new personalization algorithm
by: Neta Tsur, et al.
Published: (2019-10-01)

Public Adverse Event Data Insights into the Safety of Pembrolizumab in Melanoma Patients
by: Anne Schaefer, et al.
Published: (2020-04-01)

Cost-effectiveness analysis of pembrolizumab versus targeted therapies in advanced melanoma
by: E. G. Kosolapov, et al.
Published: (2018-05-01)

„Dyskursy Młodych Andragogów” 2016, t. 17, ss. 427
by: Magdalena Tomaszewska
Published: (2017-06-01)

Research of Mozart’s “C minor Mass” K.427
by: Yu-Mei Chen, et al.

427 Improving completion rates of electronic discharge summaries
by: Anna Athanasia Ntovolou, et al.
Published: (2021-04-01)

The treatment landscape in thyroid cancer: a focus on cabozantinib
by: Weitzman SP, et al.
Published: (2015-08-01)

304 Intratumoral injection of CMP-001, a toll-like receptor 9 (TLR9) agonist, in combination with pembrolizumab reversed programmed death receptor 1 (PD-1) blockade resistance in advanced melanoma
by: Kim Margolin, et al.
Published: (2020-11-01)

Effect of Radiotherapy Combined With Pembrolizumab on Local Tumor Control in Mucosal Melanoma Patients
by: Hyun Ju Kim, et al.
Published: (2019-09-01)

AIHA and Pancytopenia as Complications of Pembrolizumab Therapy for Metastatic Melanoma: A Case Report
by: Dan Ni, et al.
Published: (2019-06-01)

Coincident Metastatic Melanoma and Merkel Cell Carcinoma with Complete Remission on Treatment with Pembrolizumab
by: Alexander Thiem, et al.
Published: (2017-08-01)

The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma
by: Lars Ny, et al.
Published: (2021-08-01)

Overall survival in metastatic melanoma correlates with pembrolizumab exposure and T cell exhaustion markers
by: Vishal Navani, et al.
Published: (2021-08-01)

Understanding the Redox Biology of Selenium in the Search of Targeted Cancer Therapies
by: Jeffrey M. Stolwijk, et al.
Published: (2020-05-01)

Pembrolizumab reactivates pulmonary granulomatosis
by: Majdi Al-dliw, et al.
Published: (2017-01-01)